More than 350 specialists met in Barcelona to discuss earlier rheumatoid arthritis diagnosis. Biomarkers and ultrasound are helping doctors spot disease sooner and tailor treatment for thousands of patients in Spain.
More than 350 specialists met in Barcelona for the 14th Simposio de Artritis Reumatoide de la Sociedad Española de Reumatología. They focused on biomarkers, ultrasound and radiology. The aim is to prevent irreversible joint damage before it limits movement and daily life.
Rheumatoid arthritis affects about 1% of the adult population. SER and EPISER estimates cited in Spanish clinical materials put the rate at 0.82% among adults in Spain. That equals more than 300,000 people. Media reports also use an estimate of around 400,000 patients. Original event coverage puts the number of people affected in Catalonia at over 65,000.
The disease can appear at any age, including childhood and older adulthood. It can inflame the joints and affect different organs when it is not properly addressed.
ACPA, also known as anti-CCP antibodies, may be detectable before clinical symptoms appear. That makes the biomarker relevant to assessment of people who may be in an early or preclinical phase of rheumatoid arthritis.
The practical problem is not only finding the disease. Doctors need to find it before structural damage develops. Timing matters.
Susana Romero, chair of the Sociedad Española de Reumatología, said early diagnosis and treatment can prevent that damage. They can also reduce the disability linked to this high-impact condition.
Biomarkers, ultrasound and radiology give specialists more ways to detect and assess rheumatoid arthritis. Alongside rheumatoid factor and anti-CCP or ACPA, clinicians use inflammatory markers such as C-reactive protein and erythrocyte sedimentation rate. Research has also expanded knowledge of the disease's clinical and genetic dimensions. Care is moving away from one standard approach.
The goal is remission.
Doctors also want to protect quality of life and functional ability. New therapeutic targets are making more personalised treatment possible, according to Romero. Recent research has linked ultrasound, including power Doppler assessment, with disease activity measurements and the prediction of a patient's response to therapy. The approach discussed in Barcelona connects earlier detection with a closer match between the patient and the treatment.
Musculoskeletal ultrasound can show inflammation, fluid in a joint and tendon involvement directly. Quirónsalud also stresses that a normal blood test alone does not rule out arthritis, so clinical assessment, laboratory findings and imaging need to be considered together.
The new focus on diagnosis builds on an issue identified in earlier reporting about rheumatoid arthritis care in Spain. Damage can affect mobility and quality of life, so the timing of care matters. The latest discussion adds detail about the tools used to improve that timing. It does not treat diagnosis as a single clinical test.
The symposium runs from Thursday to Saturday in Barcelona. Its programme also covers treatment innovation and patient follow-up. Specialists are examining the situation of rheumatologists in Catalonia, where a possible shortage of generational replacement has been identified. Gender perspectives in rheumatoid arthritis are also on the programme.
For patients, the reported advances matter because they support earlier recognition and treatment tailored to the disease. The technology is only part of that work. Healthcare services also need to preserve function before structural damage appears and maintain specialist capacity in Catalonia.
The evidence presented does not show that rheumatoid arthritis has been overcome. It shows closer links between diagnosis, follow-up and treatment. Prevention of disability remains at the centre of care.
